uniQure (QURE) has made great progress to advance several of its gene therapy candidates in the recent year. Interim data was released from the phase I/II U.S. study of AMT-130 for the treatment of ...
uniQure N.V. (QURE) just recently reported results from its phase 1/2 study using AMT-130 for the treatment of patients with Huntington's Disease [HD]. This was interim 24-month data that showed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback